Incyte 将来の成長

NasdaqGS:INCY - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	5,131	1,275	1,537	1,577	18
12/31/2025	4,635	972	1,250	1,144	22
12/31/2024	4,202	79	193	331	22
9/30/2024	4,076	32	17	102	N/A
6/30/2024	3,857	97	-140	-61	N/A
3/31/2024	3,768	745	791	821	N/A
12/31/2023	3,696	598	449	496	N/A
9/30/2023	3,609	425	566	632	N/A
6/30/2023	3,513	366	698	781	N/A
3/31/2023	3,470	324	561	649	N/A
12/31/2022	3,395	341	892	970	N/A
9/30/2022	3,331	876	711	802	N/A
6/30/2022	3,320	945	665	760	N/A
3/31/2022	3,115	933	609	759	N/A
12/31/2021	2,986	949	568	749	N/A
9/30/2021	2,913	535	543	741	N/A
6/30/2021	2,721	338	450	668	N/A
3/31/2021	2,703	478	569	765	N/A
12/31/2020	2,667	-296	-312	-125	N/A
9/30/2020	2,457	-335	-266	-100	N/A
6/30/2020	2,388	-191	-108	-12	N/A
3/31/2020	2,229	-376	-227	-128	N/A
12/31/2019	2,159	447	633	711	N/A
9/30/2019	2,108	405	589	663	N/A
6/30/2019	2,006	306	476	592	N/A
3/31/2019	1,997	253	392	471	N/A
12/31/2018	1,882	109	263	336	N/A
9/30/2018	1,798	-109	90	163	N/A
6/30/2018	1,729	-102	N/A	17	N/A
3/31/2018	1,534	-167	N/A	101	N/A
12/31/2017	1,536	-313	N/A	-93	N/A
9/30/2017	1,419	-155	N/A	91	N/A
6/30/2017	1,306	-154	N/A	133	N/A
3/31/2017	1,226	-107	N/A	34	N/A
12/31/2016	1,106	104	N/A	305	N/A
9/30/2016	1,023	151	N/A	280	N/A
6/30/2016	941	74	N/A	193	N/A
3/31/2016	858	49	N/A	189	N/A
12/31/2015	754	7	N/A	89	N/A
9/30/2015	634	-86	N/A	61	N/A
6/30/2015	644	13	N/A	81	N/A
3/31/2015	581	-33	N/A	53	N/A
12/31/2014	511	-48	N/A	26	N/A
9/30/2014	485	-54	N/A	-30	N/A
6/30/2014	372	-136	N/A	-70	N/A
3/31/2014	374	-101	N/A	-47	N/A
12/31/2013	355	-83	N/A	9	N/A

アナリストによる今後の成長予測

収入対貯蓄率: INCYの予測収益成長率 (年間46.3% ) は貯蓄率 ( 2.6% ) を上回っています。

収益対市場: INCYの収益 ( 46.3% ) はUS市場 ( 15.3% ) よりも速いペースで成長すると予測されています。

高成長収益: INCYの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: INCYの収益 ( 8.9% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: INCYの収益 ( 8.9% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: INCYの自己資本利益率は、3年後には高くなると予測されています ( 24.7 %)

Incyte 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 13%

Consensus EPS estimates fall by 15%

Consensus EPS estimates fall by 13%

Consensus EPS estimates fall by 74%

Incyte Corporation Maintains Earnings Guidance for 2024

Incyte Corporation Provides Earnings Guidance for 2024

Recent updates

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 13%

Consensus EPS estimates fall by 15%

Incyte Corporation to Report Q3, 2024 Results on Oct 29, 2024

Consensus EPS estimates fall by 13%

Insufficient new directors

Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

Executive VP & Chief Medical Officer recently sold US$704k worth of stock

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Executive VP & Chief Medical Officer notifies of intention to sell stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP of Global Medical Affairs recently sold US$1.1m worth of stock

Consensus EPS estimates fall by 74%

Executive VP of Global Medical Affairs notifies of intention to sell stock

Incyte Corporation to Report Q2, 2024 Results on Jul 30, 2024

Incyte: The Worst Has Been Avoided

Executive VP & GM of North America recently sold US$1.1m worth of stock

Executive VP & GM of North America notifies of intention to sell stock

It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

Incyte Corporation (NasdaqGS:INCY) acquired Escient Pharmaceuticals, Inc. from a group of shareholders.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Maintains Earnings Guidance for 2024

Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.

Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024

Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)

Incyte: A Potential GARP Superstar

Incyte Corporation Provides Earnings Guidance for 2024

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Incyte Corporation to Report Q4, 2023 Results on Feb 13, 2024

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Incyte Corporation Provides Earning Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Incyte Corporation to Report Q3, 2023 Results on Oct 31, 2023

Incyte Corporation Announces Executive Changes, Effective November 1, 2023

Executive VP & Chief Medical Officer recently sold US$1.4m worth of stock

Executive VP & Chief Medical Officer notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Incyte Corporation Revises Earnings Guidance for the Year 2023

Consensus EPS estimates increase by 21%

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Incyte Corporation to Report Q2, 2023 Final Results on Aug 01, 2023

Price target decreased by 7.5% to US$82.42

Incyte Corporation Appoints Pablo J. Cagnoni, M.D. as President and Head of Research & Development, Effective June 5, 2023

Consensus EPS estimates fall by 12%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Executive VP & Chief Scientific Officer exercised options to buy US$287k worth of stock.

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

Incyte Corporation Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Insider exercised options and sold US$115k worth of stock

Incyte Corporation to Report Q4, 2022 Results on Feb 07, 2023

Executive VP & Chief Medical Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind